RBC Capital Reiterates Outperform on Surgery Partners, Maintains $49 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Ben Hendrix has reiterated an Outperform rating on Surgery Partners (NASDAQ:SGRY) and maintained a $49 price target.
August 07, 2024 | 5:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital has reiterated an Outperform rating on Surgery Partners (SGRY) and maintained a $49 price target, indicating continued confidence in the company's performance.
The reiteration of an Outperform rating and the maintenance of a $49 price target by RBC Capital suggests strong confidence in Surgery Partners' future performance. This positive analyst rating is likely to boost investor sentiment and could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100